Darolutamide Plus ADT and Radiotherapy Cuts Risk of Metastasis or Death by 58% in High-Risk Prostate Cancer
Orion Pharma has announced late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2026. The data showed that adding darolutamide, an androgen receptor inhibitor (ARi)… read more.
